Lyza

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lyza

Lyza is a prescription-only oral medication clinically recognized as a hormonal contraceptive for systemic use. It belongs to the category of Progestin-Only Oral Contraceptives (POPs), frequently referred to as the "mini-pill."

Quick Facts Description
Active ingredient Norethisterone (Norethindrone)
Form Oral Tablet
Pharmacological class Progestogen
Common use Contraception
Origin Synthetic (Second-Generation Progestin)

What is Lyza and How is it Classified?

Lyza is defined by its monotherapy composition, containing a single hormone: the active ingredient Norethisterone (also known as Norethindrone). This compound is a potent, synthetic progestogen derived from the 19-nortestosterone structure, classifying it as a second-generation progestin. The drug is delivered as an oral tablet using solid pharmaceutical excipients. Its classification as a POP fundamentally distinguishes it from combined oral contraceptives, which utilize both a progestin and an estrogenic compound, offering a simpler hormone profile. This simpler hormonal content provides a choice for individuals specifically seeking a non-estrogen containing pill.

The General Purpose of Lyza

The general purpose of Lyza is to achieve pregnancy prevention by altering the reproductive tract. The efficacy of hormonal contraceptives is characterized by their role in disrupting conception through multiple mechanisms. The action of Norethisterone is that of a potent progesterone receptor agonist, inducing a state that is resistant to conception. This specialized single-hormone composition provides a method of birth control for women who may have medical contraindications to estrogen use, underscoring its position in contraception management.

Regulatory References

  1. World Health Organization (WHO)

What side effects are possible with Lyza?

Possible Side Effects and Safety Information

The safety profile of Lyza (Norethisterone, a Progestin-Only Oral Contraceptive) is defined by regulatory documents, which classify adverse effects by frequency and the body system affected. Irregular genital bleeding is the most frequently documented adverse effect, often categorized as Common or More Common in official labeling. This includes spotting, breakthrough bleeding, and amenorrhea (absence of periods).

Other adverse reactions are formally classified under various System-Organ Classes, including Nervous System Disorders (e.g., headache, dizziness), Reproductive System and Breast Disorders (e.g., breast tenderness), and Skin and Subcutaneous Tissue Disorders (e.g., acne, chloasma, or changes in hair growth).

Classification Examples of Officially Documented Adverse Reactions
Common Headache, weight gain, breast pain, nausea
Incidence Not Known Depressed mood, fluid retention, alopecia (hair loss)

Serious Safety Considerations

The official label mandates that users and healthcare professionals remain alert to rare, serious safety risks. These include the possibility of Ectopic Pregnancy and the potential for Hepatic Neoplasia (liver tumors). The regulatory text requires that certain adverse vascular events, such as cerebral thrombosis or retinal vascular lesions, warrant evaluation and potential discontinuation of the medicine.

Safety-Related Restrictions

Lyza is strictly contraindicated (must not be used) in the presence of specific health conditions as defined in regulatory documents. These include known or suspected pregnancy, known or suspected carcinoma of the breast, and active liver disease or liver tumors. Additionally, the medication does not provide protection against HIV infection or other sexually transmitted diseases.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Lyza (Norethindrone) indicates that acute ingestion of large doses is generally associated with a low level of acute toxicity. Documented presentations of overdose are limited to non-serious effects such as nausea, vomiting, and drowsiness. In females, the ingestion of excess progestin may also result in vaginal bleeding. Inadvertent ingestion by children is generally expected to result in similar non-serious signs.

Overdose Classification and Required Actions

Regulatory documents define the severity of Norethindrone overdosage as one where serious consequences are unlikely and no serious adverse effects have been reported. The required intervention strategy is management that is exclusively symptomatic and supportive treatment, as official labeling confirms that no specific antidote is known.

When overdose occurs, seeking medical attention or contacting a poison control center is mandated for professional assessment and guidance. Immediate emergency medical help must be sought if the individual has collapsed, had a seizure, is experiencing difficulty breathing, or cannot be awakened.

This regulatory profile is characterized by the low acute toxicity of Norethindrone, which governs the non-serious nature of the expected manifestations. This classification dictates that the required emergency action is to seek immediate medical attention for professional assessment, with treatment confined to supportive care, as no specific antidote is known.

Therapeutic Uses of Lyza

What Lyza Treats: Main Uses and Benefits

Lyza is primarily utilized in the core therapeutic domain of systemic contraception. Its primary use is the prevention of pregnancy, which supports reproductive control. It is commonly used to help with the conditions of managing the need for pregnancy prevention and providing contraceptive management for patients with estrogen sensitivities.

The progestin-only formulation supports hormonal management to help address the risk of unplanned conception. This use assists with maintaining functional stability by supporting reproductive decisions as part of a long-term strategy, and thus supports the patient in their family planning goals.

“The primary benefit contributes to improved comfort by providing an effective option that is considered relevant in situations where patients experience sensitive health profiles.”

This contraceptive support is considered relevant in clinical scenarios where patients cannot take estrogen due to medical considerations or intolerance, and it is also commonly used in the context of nursing mothers (lactation).


Quick Fact Relief for
Primary Therapeutic Goal Risk of Unplanned Conception
Key Patient Group Estrogen-Intolerant Individuals

Regulatory References

  1. MedlinePlus Drug Information on Progestin-Only Contraceptives

Eligibility and Restrictions for Use

Lyza (norethindrone) is an oral contraceptive available only to specific patient populations as defined in government regulatory labeling. Eligibility is strictly limited by several absolute prohibitions and age-related restrictions.

Contraindicated Populations

Lyza must not be used by individuals who have the following conditions, as stated in the regulatory labeling:

  • Known or suspected pregnancy.
  • Known or suspected carcinoma of the breast.
  • Undiagnosed abnormal genital bleeding (requires medical evaluation before use).
  • Benign or malignant liver tumors or acute liver disease.
  • Hypersensitivity (allergy) to any component of the product.

Age and Physiological Restrictions

  • Pediatric Use: The medication should not be used before the start of menstruation (menarche). While teenagers who have started menstruating may be eligible, use in prepubescent children is not indicated.
  • Older Adults (Geriatric): Lyza is not indicated for use in elderly women, as appropriate studies on the relationship of age to the drug’s effects have not been performed in this population.
  • Breastfeeding: Use is generally permitted during breastfeeding, as studies suggest a minimal risk to the infant.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Lyza (norethindrone) can interact with a number of medicines and herbal products, primarily through the mechanism of hepatic enzyme induction. These interactions may reduce the progestin's concentration in the body, potentially diminishing its effect.

Medicines and Products with Documented Interactions

The regulatory label specifies that co-administration with drugs or herbal products that induce certain liver enzymes, such as cytochrome P450 3A4 (CYP3A4), may decrease the effectiveness of the product.

Interacting Categories and Examples:

  • Anticonvulsants: Including Phenytoin, Carbamazepine, and Barbiturates (e.g., Phenobarbital).
  • Rifamycins: Including Rifampin.
  • Anti-HIV/AIDS Medications: Including certain HIV protease inhibitors (e.g., Nelfinavir) and non-nucleoside reverse transcriptase inhibitors (e.g., Nevirapine).
  • Herbal Products: Specifically St. John’s Wort (Hypericum perforatum).

Resulting Constraints and Requirements

When co-administered with any enzyme-inducing substance, a backup, non-hormonal method of contraception is required during treatment and for a specific period after stopping the interacting drug. This is a crucial constraint detailed in official documentation to prevent loss of efficacy.

Additionally, the use of this progestin-only product may affect the results of certain laboratory tests. For example, it may decrease concentrations of Sex Hormone-Binding Globulin (SHBG) and reduce thyroxine concentrations due to a decrease in Thyroid Binding Globulin (TBG).

Mechanism of Action

Lyza's action is defined by a precise mechanism focused on modulating activity within specific physiological pathways at the molecular level. It operates through targeted interaction with core systems, influencing specific signal transduction dynamics.

Targeted Modulation of Receptor and Enzyme Systems

Lyza initiates its effect by acting on defined biological targets within specific cell surfaces, primarily functioning as a modulator within key receptor or enzyme systems. This interaction is the critical first step that alters signaling dynamics, exerting a targeted effect on key regulatory systems and initiating the mechanistic cascade.

Regulating Signal Transduction Cascades

Following receptor engagement, Lyza works within well-characterized molecular cascades to influence signal flow. It is applied to environments where heightened pathway activation and excessive mediators dominate. By initiating or suppressing specific signaling events, Lyza modifies early molecular steps that normalize or dampen excessive signaling within the pathway.

Modulation of Central and Peripheral Pathways

Lyza's overall mechanism influences core regulatory systems by adjusting activity within defined central and/or peripheral pathways. This action is relevant in systems where precise, targeted pathway adjustment is required, modulates the intensity of specific physiological responses, and reduces the magnitude of excessive mediator activity, thereby contributing to the overall pharmacological effect.

Dosage and Administration Information

Official Administration Guidelines

Lyza is a progestin-only oral contraceptive that is used according to a strict, continuous daily schedule. The administration protocol is designed for sustained systemic consistency, making precise daily timing a critical factor for use. The standard regimen is one 0.35 mg oral tablet taken once daily.


Procedural Requirements

Instruction Detail
Route of administration: Oral.
Dosing schedule: One tablet (0.35 mg) once daily.
Timing in relation to meals: May be taken with or without food.
Frequency: Continuous daily use (no interruption between packs).
Special procedural conditions: Must be taken at the same time each day; tablets must be taken in sequence

Adherence and Missed Timing Protocol

Adherence to the prescribed schedule is essential, as the effectiveness of this monotherapy relies on maintaining a critical daily time window. If a tablet is taken three or more hours later than its scheduled time, the dose is considered late. Should this occur, a non-hormonal backup contraceptive method must be employed for the next 48 hours (two days) in addition to continuing the regular tablet schedule.

Population-Specific Instructions

The standard 0.35 mg dose is applied to postpubertal adolescents. For patients in the postpartum period, the initiation of tablet-taking is often specified to begin six weeks after delivery, or according to individual clinical guidance.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Lyza

This section outlines the types of research and study findings that describe the use of Lyza (a Norethisterone Progestin-Only Oral Contraceptive). The goal is to provide a neutral overview of what has been observed in clinical research, based on regulatory and scientific documentation.


Evidence for use in Systemic Hormonal Contraception

Research exploring Lyza as a method of contraception involved both Randomized Controlled Trials (RCTs) and large observational studies. Studies monitored outcomes related to the pill’s structural capacity to disrupt conception, which is quantified by a statistic called the Pearl Index (PI)—this describes how many pregnancies occur per 100 women using the method for a year. Research highlights changes measured during the study period, with findings describing patterns observed in the studies related to the measured PI. Research examined the pill’s single-hormone composition, describing its profile as different from combined contraceptives.

What remains uncertain is the full impact of adherence requirements. Data show patterns related to the pill’s performance being highly sensitive to timing of intake, a requirement related to the short half-life of the medicine. Research is ongoing to fully characterize the long-term effectiveness of the pill compared to some newer progestin options.


Evidence for use During the Postpartum and Lactation Period

Research has explored the pill as a method of contraception during the postpartum and breastfeeding (lactating) period. This evidence is largely derived from Systematic Reviews and comparative observational studies. Studies monitored outcomes related to infant growth and development, as well as breastfeeding outcomes, such as the duration and continuation rate of breastfeeding. Systematic reviews reported patterns where the use of the pill was not consistently associated with changes in the continuation of breastfeeding.

Certainty remains low for some specific outcomes due to the nature of the studies. Evidence quality varies across studies, with many reports relying on relatively modest sample sizes or having variations in their designs. There is limited information for long-term outcomes for infants beyond the first six months of life, and data for certain groups, such as very early postpartum initiation, remain insufficient.

Key Studies & References

  1. U.S. Medical Eligibility Criteria for Contraceptive Use, 2024 (U.S. MEC) (Guidance on postpartum/estrogen contraindications)

Frequently Asked Questions (FAQ)

Common questions about Lyza (FAQ)


Q: What is Lyza actually used for, besides the main thing?

The product Lyza, which contains 0.35 mg of Norethindrone, is indicated only for the prevention of pregnancy, according to official regulatory documents. Other formulations of the active ingredient, such as Norethindrone Acetate, may be approved for conditions like endometriosis or secondary amenorrhea, but these are distinct products.


Q: Can Lyza be taken if you have kidney problems?

Regulatory labeling notes that Lyza may cause some degree of fluid retention in the body. Conditions influenced by this factor, such as existing renal dysfunctions (kidney problems), require careful observation by a healthcare professional. It is important to share a complete health history with a healthcare provider before use.


Q: Do you have to take Lyza forever?

The duration of use is determined by individual medical needs and how long contraception is desired. Limited available data suggests a rapid return of normal ovulation and fertility following discontinuation of the medication. The product may be discontinued when an individual and their healthcare provider determine it is appropriate.


Q: How long does it typically take to see a difference with Lyza?

If the first pill is started on any day other than the first day of the menstrual period, the official patient information advises using a non-hormonal backup method (like condoms) for the next 48 hours (two days). This precaution is noted in official guidelines to ensure the continuous contraceptive effect is established.


Q: What happens if I stop taking Lyza suddenly?

If the medication is discontinued, fertility will likely return quickly. The official label specifies that if an individual remains sexually active and does not wish to become pregnant, the use of another form of birth control immediately after stopping the pills is necessary.


Q: Is it normal to feel tired when starting Lyza?

Some official summaries of adverse reactions indicate that fatigue is a reported effect of the drug, sometimes classified under post-marketing data or in the 'Frequency Not Reported' categories. It is not always classified as a common occurrence in all regulatory labeling.


Q: Does Lyza make you drowsy?

Drowsiness, also known as somnolence, is a reported adverse effect documented in some official sources. However, it is typically not categorized as one of the more common side effects of the medication.


Q: Will Lyza change how my birth control works?

Regulatory documents include specific guidelines for switching between hormonal contraceptives. For example, when switching from a combined oral contraceptive (containing estrogen and progestin) to Lyza, official guidelines outline a specific procedure for tablet-taking.


Q: Can I drink alcohol while taking Lyza?

Alcohol is generally considered to have a minor interaction with the active ingredient, Norethindrone. Official drug information often advises that it is best to discuss the use of alcohol with a healthcare provider.


Q: Does Lyza interact with blood pressure medicine?

Progestin intake can cause existing blood pressure levels to rise. Official warnings state that patients with risk factors for arterial vascular disease, such as high blood pressure (hypertension), require close monitoring. It is important to review a complete health history with a healthcare provider.


Q: Can Lyza interact with over-the-counter pain relievers like ibuprofen?

Based on official data used by drug interaction checkers, there are typically no major or moderate interactions found between Lyza and common nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen.


Q: Is it okay to take Lyza with vitamins or herbal supplements?

The official label specifically notes that the herbal product St. John’s Wort can significantly reduce the effectiveness of Lyza. While general vitamins are usually not listed, all prescription drugs, over-the-counter medicines, and supplements should be reviewed by your healthcare provider for potential interactions.


Q: Is Lyza considered a high-risk medication?

Regulatory documents do not use the term 'high-risk' to categorize the medication. However, its effectiveness is highly dependent on rigid adherence to the dosing schedule. Serious risks, such as Ectopic Pregnancy, are highlighted as safety considerations that warrant awareness.


Q: How long does Lyza stay in your system?

Official pharmacokinetics data states that the mean terminal elimination half-life of the active ingredient, Norethindrone, is approximately 8 to 9 hours. This short duration is why the effectiveness of the pill is highly sensitive to the exact time of day it is taken.


Q: Are there any long-term side effects known for Lyza?

The official label notes rare, serious risks associated with progestin-only use, including the potential for Hepatic Neoplasia (liver tumors). These are considered serious safety concerns that may relate to long-term use and require awareness and periodic monitoring.


Q: Is there ongoing research about new uses for Lyza?

Clinical research is ongoing to compare the effectiveness and safety of the 0.35 mg product with other formulations of Norethindrone or newer contraceptive options. Official regulatory documents do not indicate that research is underway for new, unapproved uses of this specific product.


Q: Do I need any special tests before starting Lyza?

The official regulatory label requires a medical evaluation if an individual has undiagnosed abnormal genital bleeding before they can start using the medication. While using the medication, regulatory documents indicate that regular medical check-ups, including breast and pelvic exams, may be necessary.


Q: Can I take Lyza if I have diabetes?

Official precautions note that Lyza may have adverse effects on carbohydrate metabolism (blood sugar levels). Official precautions indicate that prediabetic and diabetic women require close monitoring by a healthcare provider during therapy to manage any metabolic changes.


Q: Is Lyza gluten-free?

The official labeling lists all active and inactive ingredients, but it does not explicitly label the final product as 'gluten-free.' For individuals with celiac disease or gluten sensitivities, it is helpful to review the full list of excipients with a healthcare provider.


Q: Are there different strengths of Lyza available?

Lyza, as an oral contraceptive, is provided specifically as a 0.35 mg tablet. While the active ingredient, Norethindrone, is available in other strengths (e.g., 5 mg), those products are used for non-contraceptive gynecological indications.


Q: Can Lyza be crushed or chewed?

The regulatory label instructs the tablet to be taken by mouth as directed. Since there is no explicit instruction to alter the tablet, it is generally assumed that the tablet should be swallowed whole to ensure the intended release and absorption of the medicine.


Q: Does Lyza affect fertility in men or women?

Lyza is only indicated for female contraception, and limited available data indicates that normal ovulation and fertility return rapidly following discontinuation of the medication. There is no official regulatory data regarding any effect on male fertility.


Q: What happens if Lyza is taken with caffeine?

Caffeine is listed as a potential minor interaction with Lyza. Your healthcare provider may give special instructions or choose to monitor you closely if you frequently use caffeine while taking this medication.


Q: Is Lyza considered a Schedule I, II, III, IV, or V drug?

Official regulatory classification documents, such as the DEA schedule in the United States, indicate that Lyza (Norethindrone) is classified as DEA Schedule: None. This means it is not a federally controlled substance.


Q: What is the purpose of the black box warning on Lyza's label?

Progestin-only oral contraceptives (POPs) typically do not have a Black Box Warning regarding cardiovascular events in the same way that combined oral contraceptives do. The main warning often highlights that the product does not protect against HIV infection and other sexually transmitted diseases.

How should Lyza be stored and disposed of?

How to Store and Dispose of Lyza?

This section explains the official, label-based requirements for storing and discarding Lyza (Norethindrone) tablets.

Storage Requirement Official Regulatory Statement
Temperature & Environment Store at Controlled Room Temperature (20°C to 25°C or 68°F to 77°F), protecting the tablets from excess heat and moisture (do not store in the bathroom).
Handling & Packaging Keep the medication in the original container it came in, tightly closed. The product must be kept from freezing. Tablets should only be removed from the blister pack just before use.
Child Safety A mandatory instruction on the label: Keep this and all medications out of the sight and reach of children in a safe, secured location.

Official Disposal Protocol

Lyza is not on the FDA Flush List and should not be discarded down the toilet or sink. The preferred method for disposal of unused or expired tablets is through a drug take-back program (e.g., mail-back envelope or take-back location). If a program is unavailable, tablets must be removed from the packaging, mixed with an undesirable substance (such as used coffee grounds), and placed in a sealed bag before being thrown into the household trash. Scratch out all personal information on the label before discarding the empty packaging.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lyza found in:

A-Z Index: